The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | SQUAT: neoadjuvant chemo-immuno-radiation and surgery in NSCLC
Gerry Hanna, MBBCh, PhD, MRCP, FRCR, FRANZCR, Trinity College Dublin, Dublin, Ireland, discusses findings from the Phase II SQUAT trial (WJOG 12119L) of neoadjuvant chemo-immuno-radiation therapy followed by surgical resection and adjuvant immunotherapy in resectable stage III-N2 non-small cell lung cancer (NSCLC). The addition of radiation therapy showed promising long-term outcomes, but further research is needed to further define resectability in lung cancer. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
